CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired Transplant Hero LLC, a New York-based provider of a mobile application supporting the needs of transplant patients.
The acquisition of Transplant Hero builds on AlloCare, the comprehensive CareDx mobile health app for managing the day-to-day health of patients before and after transplant. Transplant Hero strengthens CareDx’s focus on the transplant patient journey and adds to its growing digital portfolio which includes a robust suite of cloud-based solutions and software for transplant centers and dialysis providers.
Transplant Hero provides a smartphone app focused on helping transplant patients manage their medications through alarms and interactive logging of medication events. Medication management is especially important for transplant patients who must follow a regular regimen to protect against organ rejection. The number of pills and the complexity of the regimen often makes medication management a challenge. The app offers support to various types of organ recipients, including kidney, heart, lung, liver, pancreas, and small bowel.
“CareDx and Transplant Hero are both dedicated to improving outcomes for transplant patients,” said Reg Seeto, President and CEO, CareDx. “Transplant Hero’s easy-to-use interface and transplant focus allows us to expand into different organs. We will be able to leverage Transplant Hero’s well-established social media presence to augment AlloCare which has been built around patients from kidney transplant centers.”
“CareDx continues to make a difference in the lives of transplant patients and is a great fit for why Transplant Hero was originally founded. We are looking forward to working together to help improve the lives of individual transplant patients,” said Jay Graham, MD, MBA, FACS, Founder and CEO of Transplant Hero.